Clearmind Medicine Secures New U.S. Patent for Binge Behavior Regulators
CMND sits 21% above its 52-week low of $2.1.
Summary
Clearmind Medicine announced the grant of a new U.S. patent for its MEAI molecule and related derivatives, strengthening its intellectual property portfolio for binge behavior regulators.
Key Events · Product Development and Regulatory · CMND
-
New U.S. Patent Granted
The United States Patent and Trademark Office (USPTO) granted Patent No. 12,357,590, titled 'BINGE BEHAVIOR REGULATORS'.
-
Strengthens IP for MEAI Molecule
The patent enhances intellectual property protection for the MEAI (5-methoxy-2-aminoindane) molecule and related derivatives, targeting binge behaviors like excessive drinking and eating.
-
Builds on Existing Portfolio
This new patent directly builds on the company's previously issued U.S. Patent No. 12,350,242, further solidifying its global patent strength.
Analysis · CMND · Life Sciences
This new U.S. patent protects Clearmind Medicine's core MEAI molecule for regulating binge behaviors, including alcohol use disorder. For a clinical-stage biotech company, securing intellectual property is critical for future commercialization and provides a positive development amidst recent dilutive financing activities.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $2.10 to $524.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.